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Abstract
Objective: As data on the safety profile of Panax ginseng and Hericium erinaceum 
is lacking, the safety of these two compounds was examined in a series of toxico-
logical studies. 
Materials and Methods: MUNOPHIL, the water extract mixture of Panax ginseng 
and Hericium erinaceum was tested in an oral subchronic 28-day toxicity study in 
rats at doses of 1250, 2500 and 5000 mg/kg/day. 
Results: In repeated dose toxicity studies, no mortality was observed when varying 
doses of the extracts were administered once daily for a period of 28 days. There 
were no significant differences in body weight, absolute and relative organ weights 
between controls and treated rats of both sexes. Hematological analysis showed no 
differences in most parameters examined. In the biochemistry parameter analysis, 
no significant change occurred. Pathologically, neither gross abnormalities nor his-
topathological changes were observed. Therefore, MUNOPHIL appears to be safe 
and non-toxic in these studies and a no-observed adverse effect level in rats was 
established at 5000 mg/kg/day. 
Conclusion: The data could provide satisfactory preclinical evidence of safety to 
launch clinical trials on standardized formulation of plant extracts.
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1. Introduction
MUNOPHIL is a water extract mixture of Panax gin-
seng and Hericium erinaceum for use as an agent 
for activating vital energy and improving immune 
function. The species Panax ginseng and Hericium 
erinaceum have been identified and many are 
known to have medicinal properties [1−4]. Panax 
ginseng is a widely used and respectable anti-
cancer herb around the world [5−7] and studies 
performed in rats showed that an extract of 
Hericium erinaceum has immunomodulating func-
tions such as activating/macrophages and natural 
killer (NK) cells [8−10]. 
Even though the safety of Panax ginseng has been 
substantiated with significant scientific research 
[11−13], no systematic non-clinical toxicity studies 
have yet been performed on Hericium erinaceum. 
Early animal studies, conducted in dogs, reported no 
adverse effect of ginseng on body weight or blood 
chemistry. In mice, the LD50 for ginseng ranges from 
10 to 30 g/kg, with a lethal oral dose of purified 
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ginseng as high as 5 g/kg body weight [14]. In a 
2-year human study, 14 out of a total of 133 subjects 
were reported to experience side effects attributed 
to long-term exposure of ginseng when consumed 
at levels up to 15 g/day. Average intakes of ginseng 
were equivalent to consuming 6500 mg ginseng cap-
sules daily and produced side effects that included 
hypertension, gastrointestinal disturbances, insom-
nia and nervousness [15]. 
Hericium erinaceum has a stimulatory effect on 
interleukin (IL)-1 production in macrophages via 
activation of transcription factors such as natural 
factor (NF)-κB. It also has an inductive effect on 
macrophage activation leading to inducible nitric 
oxide synthase (iNOS) expression and nitric oxide 
(NO) production through the activation of transcrip-
tion factor NF-κB. Furthermore, Hericium erinaceum 
has an inductive effect on splenocyte-derived NK 
cell activation leading to cytolysis of Yac-1 cells 
[8−10]. Therefore, a large potential exists for the 
development of Hericium erinaceum as an immu-
nomodulating drug for cancer patients; however 
its safety is not established. Panax ginseng and 
Hericium erinaceum contain components common 
to many herbs that are routinely consumed without 
reported adverse effects. Even so, starting human 
clinical trials using these herbs is not possible with-
out evidence of safety. Because data on the safety 
profile of MUNOPHIL, the water soluble extracts of 
Panax ginseng and Hericium erinaceum, are insuf-
ficient to allow a human clinical trial, we decided 
to perform toxicological studies to evaluate the 
safety of MUNOPHIL, to build the safety evidence 
for possible future clinical trials. 
2. Materials and Methods
2.1. Test material
Dried Panax ginseng and Hericium erinaceum were 
obtained from Dunsan Oriental Hospital (Daejeon, 
Korea). MUNOPHIL containing 50% water was ex-
tracted from a mixture of Panax ginseng and Hericium 
erinaceum according to over-the-counter Korean 
monographs by Samik Pharmaceutical Company and 
used in this experiment. 
2.2. Animals and experiment 
Eighty Sprague Dawley rats (CrjBgi:CD(SD)-IGS(Rat)) 
(aged 5 weeks, 40 male, 40 female) were obtained 
from Orientbio (Gyoenggi-do, Korea). The animals 
were housed in wire cages (500 × 300 × 200 mm). 
Five rats were reared in each cage and identifica-
tion cards stating test number and animal number 
were attached to the cage. The animal room was 
maintained at a temperature of 20.1−23.1ºC, 45.2−
68.3% relative humidity and ambient light (200−
300 Lux) controlled to produce 12 h light/dark cycle. 
The animals were fed with Purina Certified Rodent 
Meal sterilized with radiation (2.0 M rad) and UV 
sterilized water ad libitum during the study. Ani-
mals were acclimated to laboratory conditions for 
at least 1 week before use.
Repeated toxicity studies were conducted on 
four groups of rats (0 mg/kg control, 1250 mg/kg low 
dose, 2500 mg/kg medium dose and 5000 mg/kg 
high dose) for 28 days. While the extract was orally 
administered using gavage to test groups, distilled 
water was administered to control group. The rats 
were observed for mortality, signs of gross toxicity 
and behavioral changes at least once daily during this 
study. Body weights and food and water consump-
tion were recorded weekly. Ophthalmological exami-
nation was conducted by observing the appearance 
of the eyes in the last week of this experiment. At 
the end of the experiment, all animals were sacri-
ficed after blood collection under deep anesthesia 
with ether. After bleeding of residual blood, internal 
organs were removed; weighted and gross findings 
were recorded. All organs were fixed and individu-
ally stored for histopathological examination. 
2.3.  Hematology, biochemistry parameters 
and urine analysis 
The animals were fasted overnight and blood was 
collected from the abdominal artery under anesthe-
sia with ether. Two milliliters of blood was trans-
ferred into a CBC bottle (EDTA 3K, Sewon Medical) 
and analyzed using an automatic hematoanalyzer, or 
blood count machine (ADVIA120E, Bayer). Blood was 
then transferred into a Vacutainer® (sodium citrate 
3.2%, USA) and centrifuged at 3000 rpm for 10 min-
utes. Plasma was isolated and used to determine 
aggregation time using a coagulometer (Coagrex-100s, 
Japan).
The hematology examinations (white blood 
cell (WBC), red blood cell (RBC), hemoglobin, he-
matocrit, mean corpuscular volumn (MCV), mean 
corpuscular hemoglobin (MCH), mean corpuscular 
hemoglobin concentration (MCHC), prothrombin time 
(PT), activated partial thromboplastin time (APTT) 
and platelets) and biochemistry examinations (total 
protein, albumin, albumin/globulin (A/G) ratio, total 
bilirubin, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), 
creatinine, blood urine nitrogen (BUN), total cho-
lesterol, triglycerides, glucose, calcium, inorganic 
phosphorus, creatinine kinase, sodium, potassium 
and chloride) were performed. Urine tests were 
performed in the last week using Bayer Diagnostics 
Multistix 10SG (Not. 5J06C, USA) REF 2300(03536597) 
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strip and urine analyzer (Clinitek 500, USA) for spe-
cific gravity, pH, leukocyte, nitrite, protein, glucose, 
ketone, urobilinogen, bilirubin and blood. 
2.4. Histopathological examination 
Internal organs were individually removed and 
fixed with 10% neutral formalin, but testes and 
epididymis were fixed with Bouin’s solution. The 
organs of the high dosage and control groups were 
used to make histological slides and examined under 
the microscope. 
2.5. Statistics
The body weight, feed and water consumption, 
hematological data, biochemistry data and organ 
weight were analyzed for homogeneity of variance 
using Levene’s test. Tests of significance were per-
formed using ANOVA analysis for homogeneous data 
and were reanalyzed with Scheffé test. All analysis 
was performed using SPSS program (Version 10.1). 
3. Results 
3.1. Survival and clinical observations 
There were no mortalities. There were no oph-
thalmologic findings or clinical observations noted 
during the study that were considered to be of bio-
logical significance. Food and water consumption 
were not statistically significantly different among 
treated groups compared with the controls (data 
not shown). 
3.2.  Body weight and relative organ 
weights 
Average overall body weight and body weight gain 
data indicated that the treated rats regardless of 
dose level were comparable to the controls. Absolute 
and relative organ weights of treated male and 
female rats indicated that there were no statisti-
cally significant differences among treated groups 
compared with the control (Table 1). 
3.3.  Hematology, biochemistry parameters 
and urine analysis 
There were no significant differences between the 
control group and any treatment group in the uri-
nalysis and hematological analysis (data not shown). 
Blood chemistry in males and females is shown in 
Table 2. Analysis of blood chemistry revealed that 
chloride levels of males in the low, middle and high 
dosage groups were increased significantly compared 
with the control, and those of females in the high 
dosage group were also significantly increased. 
3.4. Histopathological examination 
Diffuse micro lipid droplet deposits were observed 
in the liver of female and male administered groups 
as well as control. Focal lymphocyte aggregation was 
weakly observed in treatment groups in both males 
and females. In the kidneys of male control and 
administered groups, two cases of focal lymphocyte 
aggregation, one case of lymphocyte infiltration and 
cortical cystic degeneration considered to be con-
genital hypoplasia were observed. However, there 
were no considerable changes between control and 
treatment groups.
4. Discussion 
The aim of the present study was to characterize 
the potential toxic effects of MUNOPHIL, the herbal 
formula of the water extract mixture of Panax 
ginseng and Hericium erinaceum. MUNOPHIL is the 
herbal drug developed for mitigating the side-effects 
of chemotherapy or radiation therapy, increasing 
immunological activity and enhancing anti-cancer 
drug effects during chemotherapy or radiation 
therapy. 
Panax ginseng and Hericium erinaceum contain 
components common to many herbs routinely con-
sumed without reported adverse effects, but human 
clinical trials using this herbal drug cannot proceed 
without evidence of safety. Because data on the 
safety profile of MUNOPHIL, incorporating the water 
soluble extracts of Panax ginseng and Hericium 
erinaceum, are insufficient to allow human clinical 
trials, we decided to perform toxicological studies 
in rats, allowing important information about the 
toxic effects of MUNOPHIL to be determined. 
There are few reported cases of ginseng toxicity 
or descriptions of side effects attributed to either 
the quantity or quality of ginseng when taken at 
the recommended dosages. Early animal studies, 
conducted in dogs, reported no adverse effect of 
ginseng on body weight or blood chemistry. In mice, 
the LD50 for ginseng ranges from 10−30 g/kg, with 
a lethal oral dose of purified ginseng as high as 
5 g/kg body weight [14]. In a 2-year human study, 
14 out of a total of 133 subjects were reported to 
experience side effects attributed to long-term 
exposure of ginseng when consumed at levels up 
to 15 g/day. Average intakes of ginseng were equiv-
alent to consuming 6500 mg ginseng capsules daily 
and produced side effects that included hyperten-
sion, gastrointestinal disturbances, insomnia and 
nervousness [15]. 
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The possibility of more serious adverse events 
is indicated in isolated case reports and data from 
spontaneous reporting schemes; however, causal-
ity is often difficult to determine from the evidence 
provided. Possible drug interactions have been re-
ported between Panax ginseng and warfarin, phe-
nelzine and alcohol. Collectively, these data suggest 
that Panax ginseng monopreparations are rarely 
associated with adverse events or drug interactions 
[11−13].
Hericium erinaceum has a stimulatory effect on 
IL-1 production in macrophages via activation of 
transcription factors such as NF-κB. It also has an 
inductive effect on the macrophage activation lead-
ing to iNOS expression and NO production through the 
activation of transcription factor NF-κB. Further-
more, Hericium erinaceum has an inductive effect 
on splenocyte-derived NK cell activation leading to 
cytolysis of Yac-1 cells [8−10]. This demonstrates 
that Hericium erinaceum could be developed as an 
immunomodulating drug for cancer patients but 
information regarding its safety in humans is not 
available.
MUNOPHIL was therefore subsequently tested 
in an oral subchronic 28-day toxicity study in rats 
at doses of 1250, 2500 and 5000 mg/kg/day. In 
repeated dose toxicity studies, no mortality was 
observed when varying doses of the extracts were 
administered per day for a period of 28 days. There 
were no significant differences in body weight, ab-
solute and relative organ weights between controls 
and treated animals of both sexes. Hematological 
analysis showed no differences in most parameters 
examined. In the biochemistry parameter analysis, 
we observed a significantly higher value of chloride 
in males of the 1250, 2500 and 5000 mg/day group 
and females of the 5000 mg/day group compared 
with respective control groups. Chloride is derived 
from chlorine and is a chemical that our body needs 
for metabolism and for maintenance of acid-base 
balance. The amount of chloride in the blood is care-
fully controlled by the kidneys. High blood chloride 
levels may be due to the absorption of normal salt. 
These differences were not considered biologically 
relevant and were not considered treatment related 
because they did not occur with any consistent 
relationship to dose. 
There were no significant differences between 
the control group and any treatment group in the 
urinalysis during the dosing period. Pathologically, 
neither gross abnormalities nor histopathological 
changes were observed. 
From these results, oral administrations of 
MUNOPHIL appeared to be well tolerated by the 
rats. The extract seemed to have no discernable 
biologically significant toxic effect on the nervous 
system, respiratory system and other physiological 
functions of animals of both sex during single and 
repeated dose studies. The extracts had also incon-
sistent effects on body growth, organ weights and 
hematological and biochemistry parameters that 
failed to be supported by gross and histopathologic 
examinations of major organs. 
The no-observed adverse effect level (NOAEL) 
for the 28-day study with MUNOPHIL was consid-
ered to be over 5000 mg/kg/day. This data suggests 
that adverse human health effects at lower levels 
of daily exposure would not be expected. Also, 
these findings could provide satisfactory preclini-
cal evidence of safety to launch clinical trials on 
standardized formulation of plant extracts. 
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